<table>
<thead>
<tr>
<th>Adult Cancers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast (34 trials)</td>
</tr>
<tr>
<td>Cutaneous (17 trials)</td>
</tr>
<tr>
<td>Gastrointestinal (18 trials)</td>
</tr>
<tr>
<td>Genitourinary (19 trials)</td>
</tr>
<tr>
<td>Gynecological (5 trials)</td>
</tr>
<tr>
<td>Head and Neck (9 trials)</td>
</tr>
<tr>
<td>Malignant Hematology (29 trials)</td>
</tr>
<tr>
<td>Multiple / Ill-Defined Disease Sites (16 trials)</td>
</tr>
<tr>
<td>Neurologic Oncology (6 trials)</td>
</tr>
<tr>
<td>Thoracic (14 trials)</td>
</tr>
<tr>
<td>Other Trials (95 trials)</td>
</tr>
<tr>
<td><strong>Total Trials = 262</strong></td>
</tr>
<tr>
<td>UCSF Protocol No.</td>
</tr>
<tr>
<td>------------------</td>
</tr>
<tr>
<td>16752</td>
</tr>
<tr>
<td>227518</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>228014</td>
</tr>
<tr>
<td>21456</td>
</tr>
<tr>
<td>19753</td>
</tr>
<tr>
<td>16704</td>
</tr>
<tr>
<td>217510</td>
</tr>
<tr>
<td>117515</td>
</tr>
<tr>
<td>UCSF Protocol No.</td>
</tr>
<tr>
<td>------------------</td>
</tr>
<tr>
<td>Breast &gt; Breast Cancer Treatment &gt; Advanced Breast Cancer &gt; ER+</td>
</tr>
<tr>
<td>227514</td>
</tr>
<tr>
<td>23752</td>
</tr>
<tr>
<td>21758</td>
</tr>
<tr>
<td>23756</td>
</tr>
<tr>
<td>217514</td>
</tr>
<tr>
<td>157521</td>
</tr>
<tr>
<td>23757</td>
</tr>
<tr>
<td>20959</td>
</tr>
<tr>
<td>21754</td>
</tr>
<tr>
<td>UCSF Protocol No.</td>
</tr>
<tr>
<td>------------------</td>
</tr>
<tr>
<td>23758</td>
</tr>
<tr>
<td>207513</td>
</tr>
<tr>
<td>21753</td>
</tr>
<tr>
<td>227517</td>
</tr>
<tr>
<td>23751</td>
</tr>
</tbody>
</table>

**Breast > Breast Cancer Treatment > Advanced Breast Cancer > HER2+**

<table>
<thead>
<tr>
<th>UCSF Protocol No.</th>
<th>ClinicalTrials.gov Protocol</th>
<th>PI Name</th>
<th>Title</th>
<th>Protocol Type</th>
<th>Study Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>157521</td>
<td>NCT03095352</td>
<td>Rugo, Hope</td>
<td>A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease</td>
<td>Treatment</td>
<td><a href="mailto:Amy.Deluca@ucsf.edu">Amy.Deluca@ucsf.edu</a>; <a href="mailto:madeline.tait@ucsf.edu">madeline.tait@ucsf.edu</a></td>
</tr>
<tr>
<td>22756</td>
<td>NCT04829604</td>
<td>Rugo, Hope</td>
<td>A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd</td>
<td>Treatment</td>
<td><a href="mailto:Amy.Deluca@ucsf.edu">Amy.Deluca@ucsf.edu</a></td>
</tr>
<tr>
<td>ALLIANCE-A011801</td>
<td>NCT04457596</td>
<td>Rugo, Hope</td>
<td>THE COMPASSHER2 TRIALS (COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2-POSITIVE BREAST CANCER): COMPASSHER2 RESIDUAL DISEASE (RD), A DOUBLE-BLINDED, PHASE III RANDOMIZED TRIAL OF T-DM1 AND PLACEBO COMPARED WITH T-DM1 AND TUCATINIB</td>
<td>Treatment</td>
<td><a href="mailto:Amy.Deluca@ucsf.edu">Amy.Deluca@ucsf.edu</a></td>
</tr>
</tbody>
</table>

*last updated 2/1/2024*
<table>
<thead>
<tr>
<th>UCSF Protocol No.</th>
<th>ClinicalTrials.gov Protocol</th>
<th>PI Name</th>
<th>Title</th>
<th>Protocol Type</th>
<th>Study Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast &gt; Breast Cancer Treatment &gt; Advanced Breast Cancer &gt; Triple Negative</td>
<td>187519</td>
<td>NCT03971409</td>
<td>Rugo, Hope</td>
<td>Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A multicenter, multi-arm Translational Breast Cancer Research Consortium study (TBCRC 047: InCITE) MASTER PROTOCOL</td>
<td>Treatment</td>
</tr>
<tr>
<td></td>
<td>157521</td>
<td>NCT03095352</td>
<td>Rugo, Hope</td>
<td>A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease</td>
<td>Treatment</td>
</tr>
<tr>
<td></td>
<td>207513</td>
<td>NCT03990896</td>
<td>Rugo, Hope</td>
<td>Evaluation of talazoparib, a PARP inhibitor, in patients with somatic BRCA mutant metastatic breast cancer: genotyping based clinical trial</td>
<td>Treatment</td>
</tr>
<tr>
<td></td>
<td>227516</td>
<td>NCT05374512</td>
<td>Rugo, Hope</td>
<td>A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02)</td>
<td>Treatment</td>
</tr>
<tr>
<td></td>
<td>23754</td>
<td>NCT05633654</td>
<td>Rugo, Hope</td>
<td>A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy</td>
<td>Treatment</td>
</tr>
<tr>
<td></td>
<td>207533</td>
<td>NCT03941730</td>
<td>Rugo, Hope</td>
<td>Therapeutic Targeting of ER Beta in Triple Negative Breast Cancer</td>
<td>Treatment</td>
</tr>
<tr>
<td>Breast &gt; Breast Cancer Treatment &gt; Advanced Breast Cancer &gt; Phase I</td>
<td>21758</td>
<td>NCT04862663</td>
<td>Rugo, Hope</td>
<td>A Phase Ib/III, Open-Label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPITello-292)</td>
<td>Treatment</td>
</tr>
<tr>
<td>Breast &gt; Breast Cancer Treatment &gt; Early Stage Breast Cancer &gt; Invasive &gt; Neoadjuvant</td>
<td>097517</td>
<td>NCT01042379</td>
<td>Chien, Jo</td>
<td>I-SPY 2 TRIAL - Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2</td>
<td>Treatment</td>
</tr>
<tr>
<td></td>
<td>237522</td>
<td>NCT06075953</td>
<td>Esserman, Laura</td>
<td>DCIS: RECAST Trial - Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a breast cancer prevention pilot study</td>
<td>Treatment</td>
</tr>
<tr>
<td>Breast &gt; Breast Cancer Treatment &gt; Early Stage Breast Cancer &gt; In Situ &gt; Neoadjuvant</td>
<td>217519</td>
<td>NCT04893109</td>
<td>Rugo, Hope</td>
<td>A randomized phase II trial of adjuvant trastuzumab emtansine (T-DM1) followed by subcutaneous trastuzumab versus paclitaxel in combination with subcutaneous trastuzumab for Stage I HER2-positive breast cancer (ATEMPT 2.0)</td>
<td>Treatment</td>
</tr>
<tr>
<td>UCSF Protocol No.</td>
<td>ClinicalTrials.gov Protocol</td>
<td>PI Name</td>
<td>Title</td>
<td>Protocol Type</td>
<td>Study Contact</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------------</td>
<td>---------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------</td>
<td>---------------------------------------------------</td>
</tr>
<tr>
<td>20863</td>
<td>NCT04598009</td>
<td>Tsai, Katy</td>
<td>A phase II study of binimetinib in combination with imatinib in patients with advanced KIT-mutant melanoma</td>
<td>Treatment</td>
<td><a href="mailto:sonia.contrerasmartinez@ucsf.edu">sonia.contrerasmartinez@ucsf.edu</a></td>
</tr>
<tr>
<td>23858</td>
<td>NCT05907304</td>
<td>Daud, Adil</td>
<td>An open-label study to assess the safety and efficacy of narapafenib (ERAS-254) administered with trametinib in previously treated patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations [SEACRAFT-1]</td>
<td>Treatment</td>
<td><a href="mailto:sonia.contrerasmartinez@ucsf.edu">sonia.contrerasmartinez@ucsf.edu</a></td>
</tr>
<tr>
<td>228513</td>
<td>NCT05665595</td>
<td>Daud, Adil</td>
<td>A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7884A (Vibostlolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)</td>
<td>Treatment</td>
<td><a href="mailto:sonia.contrerasmartinez@ucsf.edu">sonia.contrerasmartinez@ucsf.edu</a></td>
</tr>
<tr>
<td>22853</td>
<td>NCT05086692</td>
<td>Daud, Adil</td>
<td>A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination with Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors</td>
<td>Treatment</td>
<td><a href="mailto:sonia.contrerasmartinez@ucsf.edu">sonia.contrerasmartinez@ucsf.edu</a></td>
</tr>
<tr>
<td>22859</td>
<td>NCT05578872</td>
<td>Daud, Adil</td>
<td>A Phase 1/2 Study of ANV419 as Monotherapy or in Combination With Anti-PD-1 or Anti-CTLA-4 Antibody Following Anti-PD-1/Anti-PD-L1 Antibody Treatment in Patients With Unresectable or Metastatic Cutaneous Melanoma</td>
<td>Treatment</td>
<td><a href="mailto:sonia.contrerasmartinez@ucsf.edu">sonia.contrerasmartinez@ucsf.edu</a></td>
</tr>
<tr>
<td>23855</td>
<td>NCT05933577</td>
<td>Daud, Adil</td>
<td>A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma</td>
<td>Treatment</td>
<td><a href="mailto:sonia.contrerasmartinez@ucsf.edu">sonia.contrerasmartinez@ucsf.edu</a></td>
</tr>
<tr>
<td>228510</td>
<td>NCT05571839</td>
<td>Daud, Adil</td>
<td>A Phase 1 Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors</td>
<td>Treatment</td>
<td><a href="mailto:sonia.contrerasmartinez@ucsf.edu">sonia.contrerasmartinez@ucsf.edu</a></td>
</tr>
<tr>
<td>23851</td>
<td>NCT05608291</td>
<td>Daud, Adil</td>
<td>A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA</td>
<td>Treatment</td>
<td><a href="mailto:sonia.contrerasmartinez@ucsf.edu">sonia.contrerasmartinez@ucsf.edu</a></td>
</tr>
<tr>
<td>23852</td>
<td>NCT03589339</td>
<td>Chan, Jason</td>
<td>A Phase I Study of NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated With An Anti-PD-1 Therapy</td>
<td>Treatment</td>
<td><a href="mailto:sonia.contrerasmartinez@ucsf.edu">sonia.contrerasmartinez@ucsf.edu</a></td>
</tr>
<tr>
<td>21856</td>
<td>NCT03504488</td>
<td>Tsai, Katy</td>
<td>A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF BA3021 ALONE AND IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS</td>
<td>Treatment</td>
<td><a href="mailto:sonia.contrerasmartinez@ucsf.edu">sonia.contrerasmartinez@ucsf.edu</a></td>
</tr>
<tr>
<td>22992</td>
<td>NCT05533697</td>
<td>Daud, Adil</td>
<td>Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants with Advanced Solid Tumors</td>
<td>Treatment</td>
<td><a href="mailto:sonia.contrerasmartinez@ucsf.edu">sonia.contrerasmartinez@ucsf.edu</a></td>
</tr>
<tr>
<td>22856</td>
<td>NCT05340621</td>
<td>Tsai, Katy</td>
<td>A PHASE 1B/2 STUDY OF OKI-179 PLUS BINIMETINIB IN PATIENTS WITH ADVANCED SOLID TUMORS AND ACTIVATING MUTATIONS IN THE RAS PATHWAY (PHASE 1B) AND IN PATIENTS WITH ADVANCED NRAS-MUTATED MELANOMA (PHASE 2)</td>
<td>Treatment</td>
<td><a href="mailto:sonia.contrerasmartinez@ucsf.edu">sonia.contrerasmartinez@ucsf.edu</a></td>
</tr>
<tr>
<td>21855</td>
<td>NCT04130542</td>
<td>Daud, Adil</td>
<td>An Open Label, First in Human (FIH), Phase 1 Trial of LVGN6051 as Single Agent and in Combination with Keytruda (pembrolizumab) in Advanced or Metastatic Malignancy</td>
<td>Treatment</td>
<td><a href="mailto:sonia.contrerasmartinez@ucsf.edu">sonia.contrerasmartinez@ucsf.edu</a></td>
</tr>
<tr>
<td>UCSF Protocol No.</td>
<td>ClinicalTrials.gov Protocol</td>
<td>PI Name</td>
<td>Title</td>
<td>Protocol Type</td>
<td>Study Contact</td>
</tr>
<tr>
<td>-------------------</td>
<td>-----------------------------</td>
<td>---------</td>
<td>-------</td>
<td>---------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Cutaneous &gt; Squamous Cell Carcinoma</td>
<td>20864</td>
<td>NCT04349436</td>
<td>Tsai, Katy</td>
<td>An Open-Label, Multicenter, Phase 1B Study of RP1 in Organ Transplant Recipients with Advanced Cutaneous Squamous Cell Carcinoma</td>
<td>Treatment</td>
</tr>
<tr>
<td>Cutaneous &gt; Melanoma &gt; Locally Advanced/ Metastatic</td>
<td>21851</td>
<td>NCT04835805</td>
<td>Tsai, Katy</td>
<td>A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF BELVARAFENIB AS A SINGLE AGENT AND IN COMBINATION WITH EITHER COBIMETINIB OR COBIMETINIB PLUS ATEZOLIZUMAB IN PATIENTS WITH NRAS-MUTANT ADVANCED MELANOMA WHO HAVE RECEIVED ANTI-PD-1/PD-L1 THERAPY</td>
<td>Treatment</td>
</tr>
<tr>
<td>Cutaneous &gt; Melanoma &gt; Immunotherapy</td>
<td>18991</td>
<td>NCT03486873</td>
<td>Daud, Adil</td>
<td>A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial</td>
<td>Treatment</td>
</tr>
<tr>
<td>Cutaneous &gt; Melanoma &gt; Immunotherapy &gt; Prior Immunotherapy</td>
<td>21859</td>
<td>NCT05061134</td>
<td>Tsai, Katy</td>
<td>A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition</td>
<td>Treatment</td>
</tr>
<tr>
<td>UCSF Protocol No.</td>
<td>ClinicalTrials.gov Protocol No.</td>
<td>PI Name</td>
<td>Title</td>
<td>Protocol Type</td>
<td>Study Contact</td>
</tr>
<tr>
<td>------------------</td>
<td>---------------------------------</td>
<td>---------------</td>
<td>-------------------------------------------------------------------------------------------</td>
<td>--------------------------------------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td>21458</td>
<td>NCT04787991</td>
<td>Ko, Andrew</td>
<td>A Multicenter, Open-label, Exploratory Platform Trial to Evaluate Immunotherapy Combinations with Chemotherapy for the Treatment of Patients with Previously UnTreated Metastatic Pancreatic AdenOcanceroma (REVOLUTION)</td>
<td>Treatment</td>
<td><a href="mailto:jennifer.luan@ucsf.edu">jennifer.luan@ucsf.edu</a></td>
</tr>
<tr>
<td>19721</td>
<td>NCT04221893</td>
<td>Feng, Mary</td>
<td>Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)</td>
<td>Treatment</td>
<td><a href="mailto:hewitt.chang@ucsf.edu">hewitt.chang@ucsf.edu</a></td>
</tr>
<tr>
<td>21456</td>
<td>NCT05056077</td>
<td>Van Blarigan, Erin</td>
<td>Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)</td>
<td>Supportive Care</td>
<td><a href="mailto:emontenegro@chla.usc.edu">emontenegro@chla.usc.edu</a>; <a href="mailto:erin.vanblarigan@ucsf.edu">erin.vanblarigan@ucsf.edu</a></td>
</tr>
<tr>
<td>234510</td>
<td>NCT06160752</td>
<td>Kelley, Robin</td>
<td>A Multicenter, Open-label, First-in-Human Study of TYRA-200 in Advanced Intrahepatic Cholangiocarcinoma and Other Solid Tumors with Activating FGFR2 Gene Alterations (SURF-201)</td>
<td>Treatment</td>
<td><a href="mailto:quincy.harris@ucsf.edu">quincy.harris@ucsf.edu</a></td>
</tr>
<tr>
<td>23458</td>
<td>NCT05921760</td>
<td>Kelley, Robin</td>
<td>A Phase 1/2, Safety Lead-in and Dose Expansion, Open-label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Activity of Ivosidenib in Combination with Nivolumab and Ipilimumab in Previously Treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation</td>
<td>Treatment</td>
<td><a href="mailto:quincy.harris@ucsf.edu">quincy.harris@ucsf.edu</a></td>
</tr>
<tr>
<td>A021806</td>
<td>NCT04340141</td>
<td>Ko, Andrew</td>
<td>A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer</td>
<td>Treatment</td>
<td><a href="mailto:khuong.le@ucsf.edu">khuong.le@ucsf.edu</a></td>
</tr>
<tr>
<td>NRG-GI008</td>
<td>NCT05174169</td>
<td>Eftimie, Bogdan</td>
<td>NRG-GI008: COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)</td>
<td>Treatment</td>
<td><a href="mailto:Bogdan.Eftimie@ucsf.edu">Bogdan.Eftimie@ucsf.edu</a></td>
</tr>
<tr>
<td>21953</td>
<td>NCT04449874</td>
<td>Munster, Pamela</td>
<td>A PHASE Ia/ib DOSE-ESCALATION AND DOSE-EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS G12C MUTATION</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>19721</td>
<td>NCT04221893</td>
<td>Feng, Mary</td>
<td>Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)</td>
<td>Treatment</td>
<td><a href="mailto:hewitt.chang@ucsf.edu">hewitt.chang@ucsf.edu</a></td>
</tr>
<tr>
<td>UCSF Protocol No.</td>
<td>ClinicalTrials.gov Protocol</td>
<td>PI Name</td>
<td>Title</td>
<td>Protocol Type</td>
<td>Study Contact</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------------------</td>
<td>------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>19721</td>
<td>NCT04221893</td>
<td>Feng, Mary</td>
<td>Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic Gastrointestinal malignancies progressing on immune therapy (ARM-GI)</td>
<td>Treatment</td>
<td><a href="mailto:hewitt.chang@ucsf.edu">hewitt.chang@ucsf.edu</a></td>
</tr>
<tr>
<td>19721</td>
<td>NCT04221893</td>
<td>Feng, Mary</td>
<td>A PHASE Ia/Ib DOSE-ESCALATION AND DOSE-EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS G12C MUTATION</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>19721</td>
<td>NCT04221893</td>
<td>Feng, Mary</td>
<td>Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic Gastrointestinal malignancies progressing on immune therapy (ARM-GI)</td>
<td>Treatment</td>
<td><a href="mailto:hewitt.chang@ucsf.edu">hewitt.chang@ucsf.edu</a></td>
</tr>
<tr>
<td>19721</td>
<td>NCT04221893</td>
<td>Feng, Mary</td>
<td>Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic Gastrointestinal malignancies progressing on immune therapy (ARM-GI)</td>
<td>Treatment</td>
<td><a href="mailto:hewitt.chang@ucsf.edu">hewitt.chang@ucsf.edu</a></td>
</tr>
<tr>
<td>19721</td>
<td>NCT04221893</td>
<td>Feng, Mary</td>
<td>Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic Gastrointestinal malignancies progressing on immune therapy (ARM-GI)</td>
<td>Treatment</td>
<td><a href="mailto:hewitt.chang@ucsf.edu">hewitt.chang@ucsf.edu</a></td>
</tr>
<tr>
<td>19721</td>
<td>NCT04221893</td>
<td>Feng, Mary</td>
<td>Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic Gastrointestinal malignancies progressing on immune therapy (ARM-GI)</td>
<td>Treatment</td>
<td><a href="mailto:hewitt.chang@ucsf.edu">hewitt.chang@ucsf.edu</a></td>
</tr>
<tr>
<td>19721</td>
<td>NCT04221893</td>
<td>Feng, Mary</td>
<td>Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic Gastrointestinal malignancies progressing on immune therapy (ARM-GI)</td>
<td>Treatment</td>
<td><a href="mailto:hewitt.chang@ucsf.edu">hewitt.chang@ucsf.edu</a></td>
</tr>
<tr>
<td>UCSF Protocol No.</td>
<td>ClinicalTrials.gov Protocol</td>
<td>PI Name</td>
<td>Title</td>
<td>Protocol Type</td>
<td>Study Contact</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------------</td>
<td>------------------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------------------</td>
<td>---------------------------------------------</td>
</tr>
<tr>
<td>Gastrointestinal &gt; Colon Cancer &gt; Resectable &gt; Adjuvant (after surgery)</td>
<td>21456</td>
<td>NCT05056077</td>
<td>Van Blarigan, Erin</td>
<td>Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)</td>
<td>Supportive Care</td>
</tr>
<tr>
<td>Gastrointestinal &gt; Hepatocellular Carcinoma (liver cancer) &gt; Metastatic/Advanced &gt; First-Line</td>
<td>214515</td>
<td>NCT04976634</td>
<td>Kelley, Robin</td>
<td>An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors</td>
<td>Treatment</td>
</tr>
<tr>
<td>Gastrointestinal &gt; Anal Cancer &gt; Localized &gt; HIV Positive</td>
<td>AMC-110</td>
<td>NCT04929028</td>
<td>Wang, Chia-Ching</td>
<td>Risk-adapted therapy for HIV-associated anal cancer</td>
<td>Treatment</td>
</tr>
<tr>
<td>Gastrointestinal &gt; Pancreatic Cancer &gt; Metastatic &gt; Second-Line and Beyond</td>
<td>224514</td>
<td>NCT05249101</td>
<td>Walker, Evan</td>
<td>A Phase 1b/2, Dose-escalation, Randomized, Multicenter Study of Maintenance Ivaltinstat plus Capecitabine or Capecitabine Monotherapy in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on First Line FOLFIRINOX Chemotherapy</td>
<td>Treatment</td>
</tr>
<tr>
<td>Gastrointestinal &gt; Esophageal and Gastric Cancer (including GE junction) &gt; Advanced (including Locally Advanced / Inoperable and Metastatic) &gt; Second-Line and Beyond</td>
<td>22454</td>
<td>NCT05221320</td>
<td>Ko, Andrew</td>
<td>A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal Malignancies Harboring MAPK Pathway Mutations (BVD-523-HCQ)</td>
<td>Treatment</td>
</tr>
<tr>
<td>Gastrointestinal &gt; Colon Cancer &gt; Advanced (including Locally Advanced / Inoperable and Metastatic) &gt; Second-Line and Beyond</td>
<td>22705</td>
<td>NCT05319314</td>
<td>Keenan, Bridget</td>
<td>A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of GCC19CART in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer</td>
<td>Treatment</td>
</tr>
<tr>
<td>Gastrointestinal &gt; Pancreatic Cancer &gt; Metastatic &gt; Second-Line and Beyond</td>
<td>187015</td>
<td>NCT03844750</td>
<td>Atreya, Chloe</td>
<td>A Phase 2 Study of Perioperative Immunotherapy in Patients with Colorectal Cancer and Resectable Hepatic Metastases</td>
<td>Treatment</td>
</tr>
<tr>
<td>Gastrointestinal &gt; Pancreatic Cancer &gt; Metastatic &gt; Second-Line and Beyond</td>
<td>22454</td>
<td>NCT05221320</td>
<td>Ko, Andrew</td>
<td>A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal Malignancies Harboring MAPK Pathway Mutations (BVD-523-HCQ)</td>
<td>Treatment</td>
</tr>
<tr>
<td>Gastrointestinal &gt; Biliary Tract Cancers (Cholangiocarcinoma) &gt; Advanced (including Locally Advanced / Inoperable and Metastatic) &gt; Second-Line and Beyond</td>
<td>22454</td>
<td>NCT05221320</td>
<td>Ko, Andrew</td>
<td>A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal Malignancies Harboring MAPK Pathway Mutations (BVD-523-HCQ)</td>
<td>Treatment</td>
</tr>
</tbody>
</table>
| Gastrointestinal > Biliary Tract Cancers (Cholangiocarcinoma) > Advanced (including Locally Advanced / Inoperable and Metastatic) > Second-Line and Beyond | 23457 | NCT05506943 | Kelley, Robin | A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen | Treatment | 1-877-827-3222
<table>
<thead>
<tr>
<th>UCSF Protocol No.</th>
<th>ClinicalTrials.gov Protocol</th>
<th>PI Name</th>
<th>Title</th>
<th>Protocol Type</th>
<th>Study Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal &gt; Colon Cancer &gt; Advanced (including Locally Advanced / Inoperable and Metastatic) &gt; Second-Line and Beyond</td>
<td>NCT05039177</td>
<td>Atreya, Chloe</td>
<td>A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Advanced Gastrointestinal Malignancies (HERKULES-3)</td>
<td>Treatment</td>
<td><a href="mailto:marin.pollak@ucsf.edu">marin.pollak@ucsf.edu</a></td>
</tr>
<tr>
<td>Gastrointestinal &gt; Pancreatic Cancer &gt; Metastatic &gt; Second-Line and Beyond</td>
<td>NCT04976634</td>
<td>Kelley, Robin</td>
<td>An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors</td>
<td>Treatment</td>
<td><a href="mailto:Noor.Ayat@ucsf.edu">Noor.Ayat@ucsf.edu</a>; <a href="mailto:quincy.harris@ucsf.edu">quincy.harris@ucsf.edu</a></td>
</tr>
<tr>
<td>Gastrointestinal &gt; Biliary Tract Cancers (Cholangiocarcinoma) &gt; Advanced (including Locally Advanced / Inoperable and Metastatic) &gt; Second-Line and Beyond</td>
<td>NCT04976634</td>
<td>Kelley, Robin</td>
<td>An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors</td>
<td>Treatment</td>
<td><a href="mailto:Noor.Ayat@ucsf.edu">Noor.Ayat@ucsf.edu</a>; <a href="mailto:quincy.harris@ucsf.edu">quincy.harris@ucsf.edu</a></td>
</tr>
<tr>
<td>Gastrointestinal &gt; Colon Cancer &gt; Advanced (including Locally Advanced / Inoperable and Metastatic) &gt; Second-Line and Beyond &gt; K-ras mutant</td>
<td>NCT05221320</td>
<td>Ko, Andrew</td>
<td>A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal Malignancies Harboring MAPK Pathway Mutations (BVD-523-HCQ)</td>
<td>Treatment</td>
<td><a href="mailto:marin.pollak@ucsf.edu">marin.pollak@ucsf.edu</a></td>
</tr>
<tr>
<td>Gastrointestinal &gt; Colon Cancer &gt; Advanced (including Locally Advanced / Inoperable and Metastatic) &gt; Second-Line and Beyond &gt; K-ras wild-type</td>
<td>NCT04976634</td>
<td>Kelley, Robin</td>
<td>An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors</td>
<td>Treatment</td>
<td><a href="mailto:Noor.Ayat@ucsf.edu">Noor.Ayat@ucsf.edu</a>; <a href="mailto:quincy.harris@ucsf.edu">quincy.harris@ucsf.edu</a></td>
</tr>
<tr>
<td>Gastrointestinal &gt; Rectal Cancer &gt; Advanced (including Locally Advanced / Inoperable and Metastatic) &gt; Second-Line and Beyond &gt; K-ras mutant</td>
<td>NCT05221320</td>
<td>Ko, Andrew</td>
<td>A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal Malignancies Harboring MAPK Pathway Mutations (BVD-523-HCQ)</td>
<td>Treatment</td>
<td><a href="mailto:marin.pollak@ucsf.edu">marin.pollak@ucsf.edu</a></td>
</tr>
<tr>
<td>Gastrointestinal &gt; Neuroendocrine Tumors (NET) &gt; Well-Differentiated Neuroendocrine Tumor &gt; Pancreatic NET &gt; Metastatic / Unresectable &gt; Liver-Directed</td>
<td>NCT05477576</td>
<td>Lawhn Heath, Courtney</td>
<td>Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)</td>
<td>Treatment</td>
<td><a href="mailto:faaiz.ibrahim@ucsf.edu">faaiz.ibrahim@ucsf.edu</a></td>
</tr>
<tr>
<td>UCSF Protocol No.</td>
<td>ClinicalTrials.gov Protocol</td>
<td>PI Name</td>
<td>Title</td>
<td>Protocol Type</td>
<td>Study Contact</td>
</tr>
<tr>
<td>-------------------</td>
<td>-----------------------------</td>
<td>---------</td>
<td>-------</td>
<td>---------------</td>
<td>---------------</td>
</tr>
<tr>
<td><strong>Genitourinary &gt; Bladder Cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21456</td>
<td>NCT05056077</td>
<td>Van Blarigan, Erin</td>
<td>Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)</td>
<td>Supportive Care</td>
<td><a href="mailto:emontenegro@chla.usc.edu">emontenegro@chla.usc.edu</a>; <a href="mailto:erin.vanblarigan@ucsf.edu">erin.vanblarigan@ucsf.edu</a></td>
</tr>
<tr>
<td>20524</td>
<td>NCT04601857</td>
<td>Koshkin, Vadim</td>
<td>A Phase 2 Study Evaluating Futibatinib (TAS 120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic Urothelial Carcinoma</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td><strong>Genitourinary &gt; Prostate Cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22554</td>
<td>NCT05396872</td>
<td>Kwon, Daniel</td>
<td>A Multi-Stage Study to Improve Informed Decision-Making for Precision Oncology in Veterans with Advanced Prostate Cancer</td>
<td>Health Services Research</td>
<td><a href="mailto:marissa.mcphaul@ucsf.edu">marissa.mcphaul@ucsf.edu</a></td>
</tr>
<tr>
<td>NRG-GU010</td>
<td>NCT05050084</td>
<td>Hong, Julian</td>
<td>NRG-GU010: PARALLEL PHASE III RANDOMIZED TRIALS OF GENOMIC-RISK STRATIFIED UNFAVORABLE INTERMEDIATE RISK PROSTATE CANCER: DE-INTENSIFICATION AND INTENSIFICATION CLINICAL TRIAL EVALUATION (GUIDANCE)</td>
<td>Treatment</td>
<td><a href="mailto:jamese.johnson@ucsf.edu">jamese.johnson@ucsf.edu</a></td>
</tr>
<tr>
<td>21456</td>
<td>NCT05056077</td>
<td>Van Blarigan, Erin</td>
<td>Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)</td>
<td>Supportive Care</td>
<td><a href="mailto:emontenegro@chla.usc.edu">emontenegro@chla.usc.edu</a>; <a href="mailto:erin.vanblarigan@ucsf.edu">erin.vanblarigan@ucsf.edu</a></td>
</tr>
<tr>
<td>NRG-GU008</td>
<td>NCT04134260</td>
<td>Hong, Julian</td>
<td>RANDOMIZED PHASE III TRIAL INCORPORATING APALUTAMIDE AND ADVANCED IMAGING INTO SALVAGE TREATMENT FOR PATIENTS WITH NODE-POSITIVE PROSTATE CANCER AFTER RADICAL PROSTATECTOMY</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td><strong>Genitourinary &gt; Renal Cell Carcinoma</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALLIANCE-A031704</td>
<td>NCT03793166</td>
<td>Desai, Arpita</td>
<td>PD-INHIBITOR (NIVOLUMAB) AND IPILIMUMAB FOLLOWED BY NIVOLUMAB VS. VEGF TKI CABOZANTINIB WITH NIVOLUMAB: A PHASE III TRIAL IN METASTATIC UNTREATED RENAL CELL CANCER [PDIGREE]</td>
<td>Treatment</td>
<td><a href="mailto:medini.rastogi@ucsf.edu">medini.rastogi@ucsf.edu</a></td>
</tr>
<tr>
<td>21456</td>
<td>NCT05056077</td>
<td>Van Blarigan, Erin</td>
<td>Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)</td>
<td>Supportive Care</td>
<td><a href="mailto:emontenegro@chla.usc.edu">emontenegro@chla.usc.edu</a>; <a href="mailto:erin.vanblarigan@ucsf.edu">erin.vanblarigan@ucsf.edu</a></td>
</tr>
<tr>
<td>20528</td>
<td>NCT04626518</td>
<td>Desai, Arpita</td>
<td>A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (KEYMAKER-U03): Substudy 03B</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td><strong>Genitourinary &gt; Testicular Cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AGCT1531</td>
<td>NCT03067181</td>
<td>Rangaswami, Arun</td>
<td>A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors</td>
<td>Treatment</td>
<td><a href="mailto:Hyunju.Lee@ucsf.edu">Hyunju.Lee@ucsf.edu</a></td>
</tr>
<tr>
<td><strong>Genitourinary &gt; Prostate Cancer &gt; Metastatic Castration Sensitive</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21559</td>
<td>NCT05127850</td>
<td>Kwon, Daniel</td>
<td>mHealth ElectroNic COnsultation REcording (MENCORE-2): an implementation trial to improve informed treatment decision-making in men with advanced prostate cancer</td>
<td>Health Services Research</td>
<td><a href="mailto:GUtrials@ucsf.edu">GUtrials@ucsf.edu</a></td>
</tr>
<tr>
<td>UCSF Protocol No.</td>
<td>ClinicalTrials.gov Protocol</td>
<td>PI Name</td>
<td>Title</td>
<td>Protocol Type</td>
<td>Study Contact</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------------</td>
<td>------------------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>21559</td>
<td>NCT05127850</td>
<td>Kwon, Daniel</td>
<td>Mhealth ElectroNic COnsultation REcording (MENCORE-2): an implementation trial to improve informed treatment decision-making in men with advanced prostate cancer</td>
<td>Health Services Research</td>
<td><a href="mailto:GUtrials@ucsf.edu">GUtrials@ucsf.edu</a></td>
</tr>
<tr>
<td>21559</td>
<td>NCT05127850</td>
<td>Kwon, Daniel</td>
<td>Mhealth ElectroNic COnsultation REcording (MENCORE-2): an implementation trial to improve informed treatment decision-making in men with advanced prostate cancer</td>
<td>Health Services Research</td>
<td><a href="mailto:GUtrials@ucsf.edu">GUtrials@ucsf.edu</a></td>
</tr>
<tr>
<td>175519</td>
<td>NCT03503344</td>
<td>Aggarwal, Rahul</td>
<td>A Randomized, Phase II Study of Apalutamide +/- Stereotactic Body Radiotherapy (SBRT) in Castration-Resistant Prostate Cancer Patients with Oligometastatic Disease on PSMA-PET Imaging</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>209210</td>
<td>NCT05245006</td>
<td>Flavell, Robert</td>
<td>A First-in-Human, Pilot PET imaging Study of 89Zr-DFO-YS5, an immunoPET agent for detecting CD46 positive malignancy in men with Prostate Cancer</td>
<td>Diagnostic</td>
<td><a href="mailto:maya.aslam@ucsf.edu">maya.aslam@ucsf.edu</a></td>
</tr>
<tr>
<td>23553</td>
<td>NCT06171139</td>
<td>Kwon, Daniel</td>
<td>Developing and testing a patient-centered tumor genomic pre-test counseling tool for Black or African-American men with metastatic prostate cancer</td>
<td>Health Services Research</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>23921</td>
<td>NCT05888532</td>
<td>Aggarwal, Rahul</td>
<td>A First-in-Human, Phase I/II PET imaging Study of 64Cu-GRIP B, a Radiotracer Targeting Granzyme B, in Patients with Advanced Malignancies</td>
<td>Diagnostic</td>
<td><a href="mailto:khadija.siddiqua@ucsf.edu">khadija.siddiqua@ucsf.edu</a>; <a href="mailto:maya.aslam@ucsf.edu">maya.aslam@ucsf.edu</a></td>
</tr>
<tr>
<td>18702</td>
<td>NCT03821246</td>
<td>Fong, Lawrence</td>
<td>An open-label multi-center phase II study of neoadjuvant atezolizumab-based combination therapy in men with localized prostate cancer prior to radical prostatectomy</td>
<td>Treatment</td>
<td><a href="mailto:Julie.McCluggage@ucsf.edu">Julie.McCluggage@ucsf.edu</a></td>
</tr>
<tr>
<td>23922</td>
<td>NCT05851365</td>
<td>Flavell, Robert</td>
<td>A pilot study of magnetic resonance (MR) imaging with hyperpolarized bicarbonate (13C) to measure tissue pH in localized prostate cancer</td>
<td>Diagnostic</td>
<td><a href="mailto:maya.aslam@ucsf.edu">maya.aslam@ucsf.edu</a></td>
</tr>
<tr>
<td>22524</td>
<td>NCT04879329</td>
<td>Koshkin, Vadim</td>
<td>A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination with Pembrolizumab in Subjects with Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>21556</td>
<td>NCT04986423</td>
<td>Aggarwal, Rahul</td>
<td>A Randomized Phase 2b Study of ZEN003694 in Combination With Enzalutamide Versus Enzalutamide Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>23551</td>
<td>NCT05766371</td>
<td>Aggarwal, Rahul</td>
<td>A Phase 2 Study of Pembrolizumab Plus 177Lu-PSMA-617 in Patients with Metastatic Castration Resistant Prostate Cancer</td>
<td>Treatment</td>
<td><a href="mailto:GUtrials@ucsf.edu">GUtrials@ucsf.edu</a></td>
</tr>
<tr>
<td>21555</td>
<td>NCT05011188</td>
<td>Aggarwal, Rahul</td>
<td>A Phase 1b/2 Study of FOR46 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer</td>
<td>Treatment</td>
<td><a href="mailto:GUtrials@ucsf.edu">GUtrials@ucsf.edu</a></td>
</tr>
</tbody>
</table>

(last updated 2/1/2024)
<table>
<thead>
<tr>
<th>UCSF Protocol No.</th>
<th>ClinicalTrials.gov Protocol</th>
<th>PI Name</th>
<th>Title</th>
<th>Protocol Type</th>
<th>Study Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>21456</td>
<td>NCT05056077</td>
<td>Van Blarigan, Erin</td>
<td>Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)</td>
<td>Supportive Care</td>
<td><a href="mailto:emontenegro@chla.usc.edu">emontenegro@chla.usc.edu</a>; <a href="mailto:erin.vanblarigan@ucsf.edu">erin.vanblarigan@ucsf.edu</a></td>
</tr>
<tr>
<td>224010</td>
<td>NCT04606914</td>
<td>Chapman, Jocelyn</td>
<td>Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor alpha positive</td>
<td>Treatment</td>
<td><a href="mailto:Nathalie.Halley2@ucsf.edu">Nathalie.Halley2@ucsf.edu</a></td>
</tr>
<tr>
<td>21456</td>
<td>NCT05056077</td>
<td>Van Blarigan, Erin</td>
<td>Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)</td>
<td>Supportive Care</td>
<td><a href="mailto:emontenegro@chla.usc.edu">emontenegro@chla.usc.edu</a>; <a href="mailto:erin.vanblarigan@ucsf.edu">erin.vanblarigan@ucsf.edu</a></td>
</tr>
<tr>
<td>AGCT1531</td>
<td>NCT03067181</td>
<td>Rangaswami, Arun</td>
<td>A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors</td>
<td>Treatment</td>
<td><a href="mailto:Hyunju.Lee@ucsf.edu">Hyunju.Lee@ucsf.edu</a></td>
</tr>
<tr>
<td>23701</td>
<td>NCT05617755</td>
<td>Alvarez, Edwin</td>
<td>An Open-Label Phase 1 Study to Evaluate The Safety And Efficacy of AB-1015 In Patients With Platinum-Resistant Epithelial Ovarian Cancer</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>23701</td>
<td>NCT05617755</td>
<td>Alvarez, Edwin</td>
<td>An Open-Label Phase 1 Study to Evaluate The Safety And Efficacy of AB-1015 In Patients With Platinum-Resistant Epithelial Ovarian Cancer</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>22405</td>
<td>NCT05257408</td>
<td>Alvarez, Edwin</td>
<td>A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)</td>
<td>Treatment</td>
<td><a href="mailto:Chetna.Nangia@ucsf.edu">Chetna.Nangia@ucsf.edu</a>; <a href="mailto:Nathalie.Halley2@ucsf.edu">Nathalie.Halley2@ucsf.edu</a></td>
</tr>
</tbody>
</table>

last updated 2/1/2024
<table>
<thead>
<tr>
<th>UCSF Protocol No.</th>
<th>ClinicalTrials.gov Protocol</th>
<th>PI Name</th>
<th>Title</th>
<th>Protocol Type</th>
<th>Study Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRG-HN009</td>
<td>NCT05050162</td>
<td>Chan, Jason</td>
<td>NRG-HN009: RANDOMIZED PHASE II/III TRIAL OF RADIATION WITH CISPLATIN AT 100 MG/M2 EVERY THREE WEEKS VERSUS RADIATION WITH WEEKLY CISPLATIN AT 40 MG/M2 FOR PATIENTS WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)</td>
<td>Treatment</td>
<td><a href="mailto:jamese.johnson@ucsf.edu">jamese.johnson@ucsf.edu</a></td>
</tr>
<tr>
<td>22721</td>
<td>NCT05273307</td>
<td>Yom, Sue</td>
<td>Addressing taste dysfunction with miraculin in head and neck cancer patients receiving radiation therapy: A double-blinded, placebo-controlled, randomized phase III trial</td>
<td>Supportive Care</td>
<td><a href="mailto:jamese.johnson@ucsf.edu">jamese.johnson@ucsf.edu</a></td>
</tr>
<tr>
<td>22721</td>
<td>NCT05273307</td>
<td>Yom, Sue</td>
<td>Addressing taste dysfunction with miraculin in head and neck cancer patients receiving radiation therapy: A double-blinded, placebo-controlled, randomized phase III trial</td>
<td>Supportive Care</td>
<td><a href="mailto:jamese.johnson@ucsf.edu">jamese.johnson@ucsf.edu</a></td>
</tr>
<tr>
<td>21728</td>
<td>NCT04883671</td>
<td>Yom, Sue</td>
<td>Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR trial</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>22991</td>
<td>NCT05241834</td>
<td>Kang, Hyunseok</td>
<td>A Phase 1 Study of Oral LOXO-260 in Patients with RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation Refractory to Selective RET Inhibitors</td>
<td>Treatment</td>
<td><a href="mailto:angelica.valadez@ucsf.edu">angelica.valadez@ucsf.edu</a></td>
</tr>
<tr>
<td>228011</td>
<td>NCT05421689</td>
<td>Rosen, Clark</td>
<td>A Multi-Center, Double-Blind, Randomized Placebo-Controlled Investigation of Autologous Muscle Derived Cells (AMDC) for the Treatment of Tongue Dysphagia Resulting from the Treatment of Head and Neck Cancer (REVIVE)</td>
<td>Supportive Care</td>
<td><a href="mailto:Christina.Chun@ucsf.edu">Christina.Chun@ucsf.edu</a>; <a href="mailto:allyson.beaulieu@ucsf.edu">allyson.beaulieu@ucsf.edu</a></td>
</tr>
<tr>
<td>22203</td>
<td>NCT04892173</td>
<td>Yom, Sue</td>
<td>A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy-ineligible Elderly Patients with Locally Advanced Head &amp; Neck Squamous Cell Carcinoma</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>22207</td>
<td>NCT05287113</td>
<td>Algazi, Alain</td>
<td>A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS greater than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck</td>
<td>Treatment</td>
<td><a href="mailto:angelica.valadez@ucsf.edu">angelica.valadez@ucsf.edu</a></td>
</tr>
<tr>
<td>23201</td>
<td>NCT05653882</td>
<td>Algazi, Alain</td>
<td>An Open-Label Phase 1a/1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination with Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors</td>
<td>Treatment</td>
<td><a href="mailto:angelica.valadez@ucsf.edu">angelica.valadez@ucsf.edu</a></td>
</tr>
<tr>
<td>UCSF Protocol No.</td>
<td>ClinicalTrials.gov Protocol</td>
<td>PI Name</td>
<td>Title</td>
<td>Protocol Type</td>
<td>Study Contact</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------------------</td>
<td>---------</td>
<td>-------</td>
<td>---------------</td>
<td>---------------</td>
</tr>
<tr>
<td>177018</td>
<td>NCT03708224</td>
<td>Algazi, Alain</td>
<td>A Phase II Study of Preoperative Immunotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck</td>
<td>Treatment</td>
<td><a href="mailto:kira.chan@ucsf.edu">kira.chan@ucsf.edu</a></td>
</tr>
<tr>
<td>UCSF Protocol No.</td>
<td>ClinicalTrials.gov Protocol</td>
<td>PI Name</td>
<td>Title</td>
<td>Protocol Type</td>
<td>Study Contact</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------------------</td>
<td>----------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------</td>
<td>---------------------------------------------------</td>
</tr>
<tr>
<td>22257</td>
<td>NCT05682170</td>
<td>Smith, Catherine</td>
<td>A Phase 1/2 Dose Escalation Study of the BCL-2 Inhibitor ZN-d5 and the Wee1 Inhibitor ZN-c3 in Subjects with Acute Myeloid Leukemia</td>
<td>Treatment</td>
<td><a href="mailto:Jenai.Wilmoth@ucsf.edu">Jenai.Wilmoth@ucsf.edu</a></td>
</tr>
<tr>
<td>17251</td>
<td>NCT03013998</td>
<td>Olin, Rebecca</td>
<td>A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)</td>
<td>Treatment</td>
<td><a href="mailto:Jenai.Wilmoth@ucsf.edu">Jenai.Wilmoth@ucsf.edu</a>; <a href="mailto:alicia.aschauer@ucsf.edu">alicia.aschauer@ucsf.edu</a></td>
</tr>
<tr>
<td>212531</td>
<td>NCT05351593</td>
<td>Rubenstein, James</td>
<td>A Phase I/II Study of Tafasitamab plus Lenalidomide in Relapsed CNS Lymphoma</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>23252</td>
<td>NCT05041309</td>
<td>Logan, Aaron</td>
<td>Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells</td>
<td>Other</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>212518</td>
<td>NCT03870750</td>
<td>Olin, Rebecca</td>
<td>Seamless Phase II-Phase III Randomized Clinical Trial to Identify and Confirm the Most Promising Novel Intervention to Alleviate Morbidity and Mortality after Allogeneic Hematopoietic Cell Transplantation Among Older, Medically Infirm, or Frail Patients with Hematological Diseases</td>
<td>Supportive Care</td>
<td><a href="mailto:Jenai.Wilmoth@ucsf.edu">Jenai.Wilmoth@ucsf.edu</a></td>
</tr>
<tr>
<td>21257</td>
<td>NCT04372433</td>
<td>Dunavin, Neil</td>
<td>A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered IO-202 and IO-202 + Azacitidine ± Venetoclax in Acute Myeloid Leukemia (AML) Patients with Monocytic Differentiation and in Chronic Myelomonocytic Leukemia (CMML) Patients</td>
<td>Treatment</td>
<td><a href="mailto:Jenai.Wilmoth@ucsf.edu">Jenai.Wilmoth@ucsf.edu</a></td>
</tr>
<tr>
<td>16252</td>
<td>NCT02445222</td>
<td>Andreadis, Charalambos</td>
<td>Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy</td>
<td>Other</td>
<td><a href="mailto:Jenai.Wilmoth@ucsf.edu">Jenai.Wilmoth@ucsf.edu</a></td>
</tr>
<tr>
<td>ALLIANCE- A051901</td>
<td>NCT04609046</td>
<td>Rubenstein, James</td>
<td>Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma</td>
<td>Treatment</td>
<td><a href="mailto:Jenai.Wilmoth@ucsf.edu">Jenai.Wilmoth@ucsf.edu</a></td>
</tr>
<tr>
<td>ECOG-ACRIN- EA4151</td>
<td>NCT03267433</td>
<td>Spinner, Michael</td>
<td>A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission</td>
<td>Treatment</td>
<td><a href="mailto:Jenai.Wilmoth@ucsf.edu">Jenai.Wilmoth@ucsf.edu</a></td>
</tr>
<tr>
<td>22706</td>
<td>NCT05169515</td>
<td>Andreadis, Charalambos</td>
<td>A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB OR GLOFITAMAB IN COMBINATION WITH CC-220 AND CC-99282 IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>20924</td>
<td>NCT04656431</td>
<td>Rubenstein, James</td>
<td>Pilot Study of Feasibility of Acquiring Hyperpolarized Imaging in Patients with Primary CNS Lymphoma</td>
<td>Diagnostic</td>
<td><a href="mailto:James.Rubenstein@ucsf.edu">James.Rubenstein@ucsf.edu</a>; <a href="mailto:Wendy.Ma@ucsf.edu">Wendy.Ma@ucsf.edu</a></td>
</tr>
<tr>
<td>UCSF Protocol No.</td>
<td>ClinicalTrials.gov Protocol</td>
<td>PI Name</td>
<td>Title</td>
<td>Protocol Type</td>
<td>Study Contact</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------------</td>
<td>------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>23925</td>
<td>NCT05892393</td>
<td>Flavell, Robert</td>
<td>Pilot PET Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma</td>
<td>Diagnostic</td>
<td><a href="mailto:maya.aslam@ucsf.edu">maya.aslam@ucsf.edu</a></td>
</tr>
<tr>
<td>202515</td>
<td>NCT04504825</td>
<td>Chung, Alfred</td>
<td>A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naive Patients With Mayo Stage IIIb AL Amyloidosis</td>
<td>Treatment</td>
<td><a href="mailto:Jenai.Wilmoth@ucsf.edu">Jenai.Wilmoth@ucsf.edu</a></td>
</tr>
<tr>
<td>202523</td>
<td>NCT04663347</td>
<td>Andreadis, Charalambos</td>
<td>A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)</td>
<td>Treatment</td>
<td><a href="mailto:Jenai.Wilmoth@ucsf.edu">Jenai.Wilmoth@ucsf.edu</a></td>
</tr>
<tr>
<td>222513</td>
<td>NCT05210790</td>
<td>Leavitt, Andrew</td>
<td>A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>212526</td>
<td>NCT04994717</td>
<td>Logan, Aaron</td>
<td>Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run in (Golden Gate Study)</td>
<td>Treatment</td>
<td><a href="mailto:Jenai.Wilmoth@ucsf.edu">Jenai.Wilmoth@ucsf.edu</a></td>
</tr>
<tr>
<td>212523</td>
<td>NCT05011058</td>
<td>Ai, Weiyun</td>
<td>An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas</td>
<td>Treatment</td>
<td><a href="mailto:Jenai.Wilmoth@ucsf.edu">Jenai.Wilmoth@ucsf.edu</a></td>
</tr>
<tr>
<td>22253</td>
<td>NCT05486481</td>
<td>Chung, Alfred</td>
<td>A Multicenter Phase 1/2 study of Venetoclax / Daratumumab / Dexamethasone for Previously Treated Systemic Light-Chain Amyloidosis Patients with Translocation (11;14) (ALTITUDE STUDY)</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>212528</td>
<td>NCT04923893</td>
<td>Kumar, Anupama</td>
<td>A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>212536</td>
<td>NCT05201781</td>
<td>Martin, Tom</td>
<td>Long-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel</td>
<td>Other</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>UCSF Protocol No.</td>
<td>ClinicalTrials.gov Protocol</td>
<td>PI Name</td>
<td>Title</td>
<td>Protocol Type</td>
<td>Study Contact</td>
</tr>
<tr>
<td>-------------------</td>
<td>------------------------------</td>
<td>------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------------</td>
<td>-----------------------------------------</td>
</tr>
<tr>
<td>Malignant Hematology &gt; Hodgkin Disease &gt; Relapsed / Refractory</td>
<td>212523</td>
<td>NCT05011058</td>
<td>Ai, Weiyun</td>
<td>An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas</td>
<td>Treatment</td>
</tr>
<tr>
<td>Malignant Hematology &gt; Multiple Myeloma (MM) &gt; Relapsed / Refractory</td>
<td>212537</td>
<td>NCT05347485</td>
<td>Martin, Tom</td>
<td>A Safety and Efficacy Study of JNJ-68284528 (ciltaclabtagene autoleucel) Out-of-Specification (OOS) for Commercial Release in Patients with Multiple Myeloma</td>
<td>Treatment</td>
</tr>
<tr>
<td>Malignant Hematology &gt; Blood and Marrow Transplant (BMT) &gt; Preparative Regimen / Donor Source</td>
<td>212522</td>
<td>NCT04904588</td>
<td>Logan, Aaron</td>
<td>ACCESS: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies</td>
<td>Treatment</td>
</tr>
<tr>
<td>Malignant Hematology &gt; Chronic Lymphocytic Leukemia (CLL) &gt; Blood and Marrow Transplant (BMT)</td>
<td>212522</td>
<td>NCT04904588</td>
<td>Logan, Aaron</td>
<td>ACCESS: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies</td>
<td>Treatment</td>
</tr>
<tr>
<td>Malignant Hematology &gt; Chronic Myeloid Leukemia (CML) &gt; Blood and Marrow Transplant (BMT)</td>
<td>212522</td>
<td>NCT04904588</td>
<td>Logan, Aaron</td>
<td>ACCESS: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies</td>
<td>Treatment</td>
</tr>
<tr>
<td>Malignant Hematology &gt; Chronic Lymphocytic Leukemia (CLL) &gt; Blood and Marrow Transplant (BMT)</td>
<td>212518</td>
<td>NCT03870750</td>
<td>Olin, Rebecca</td>
<td>Seamless Phase II-Phase III Randomized Clinical Trial to Identify and Confirm the Most Promising Novel Intervention to Alleviate Morbidity and Mortality after Allogeneic Hematopoietic Cell Transplantation Among Older, Medically Infirm, or Frail Patients with Hematological Diseases</td>
<td>Supportive Care</td>
</tr>
<tr>
<td>Malignant Hematology &gt; Acute Lymphoblastic Leukemia (ALL) &gt; Relapsed / Refractory</td>
<td>212524</td>
<td>NCT04811560</td>
<td>Dunavin, Neil</td>
<td>A First in Human Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Participants with Acute Leukemia</td>
<td>Treatment</td>
</tr>
<tr>
<td>Malignant Hematology &gt; Acute Lymphoblastic Leukemia (ALL) &gt; Relapsed / Refractory</td>
<td>APAL2020SC</td>
<td>NCT04726241</td>
<td>Stieglitz, Elliot</td>
<td>Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias</td>
<td>Screening</td>
</tr>
</tbody>
</table>

(last updated 2/1/2024)
<table>
<thead>
<tr>
<th>UCSF Protocol No.</th>
<th>ClinicalTrials.gov Protocol</th>
<th>PI Name</th>
<th>Title</th>
<th>Protocol Type</th>
<th>Study Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>212524</td>
<td>NCT04811560</td>
<td>Dunavin, Neil</td>
<td>A First in Human Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Participants with Acute Leukemia</td>
<td>Treatment</td>
<td><a href="mailto:Jenai.Wilmoth@ucsf.edu">Jenai.Wilmoth@ucsf.edu</a></td>
</tr>
<tr>
<td>21257</td>
<td>NCT04372433</td>
<td>Dunavin, Neil</td>
<td>A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered IO-202 and IO-202 + Azacitidine ± Venetoclax in Acute Myeloid Leukemia (AML) Patients with Monocytic Differentiation and in Chronic Myelomonocytic Leukemia (CMML) Patients</td>
<td>Treatment</td>
<td><a href="mailto:Jenai.Wilmoth@ucsf.edu">Jenai.Wilmoth@ucsf.edu</a></td>
</tr>
<tr>
<td>207019</td>
<td>NCT03190278</td>
<td>Olin, Rebecca</td>
<td>Phase I, open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), administered in patients with Relapsed/Refractory Acute Myeloid Leukemia</td>
<td>Treatment</td>
<td><a href="mailto:Julie.McCluggage@ucsf.edu">Julie.McCluggage@ucsf.edu</a></td>
</tr>
<tr>
<td>APAL2020SC</td>
<td>NCT04726241</td>
<td>Stieglitz, Elliot</td>
<td>Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias</td>
<td>Screening</td>
<td><a href="mailto:Katherine.wu@ucsf.edu">Katherine.wu@ucsf.edu</a>; <a href="mailto:jorge.barahona@ucsf.edu">jorge.barahona@ucsf.edu</a></td>
</tr>
<tr>
<td>212518</td>
<td>NCT03870750</td>
<td>Olin, Rebecca</td>
<td>Seamless Phase II-Phase III Randomized Clinical Trial to Identify and Confirm the Most Promising Novel Intervention to Alleviate Morbidity and Mortality after Allogeneic Hematopoietic Cell Transplantation Among Older, Medically Infirm, or Frail Patients with Hematological Diseases</td>
<td>Supportive Care</td>
<td><a href="mailto:Jenai.Wilmoth@ucsf.edu">Jenai.Wilmoth@ucsf.edu</a></td>
</tr>
<tr>
<td>212518</td>
<td>NCT03870750</td>
<td>Olin, Rebecca</td>
<td>Seamless Phase II-Phase III Randomized Clinical Trial to Identify and Confirm the Most Promising Novel Intervention to Alleviate Morbidity and Mortality after Allogeneic Hematopoietic Cell Transplantation Among Older, Medically Infirm, or Frail Patients with Hematological Diseases</td>
<td>Supportive Care</td>
<td><a href="mailto:Jenai.Wilmoth@ucsf.edu">Jenai.Wilmoth@ucsf.edu</a></td>
</tr>
<tr>
<td>212522</td>
<td>NCT04904588</td>
<td>Logan, Aaron</td>
<td>ACCESS: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies</td>
<td>Treatment</td>
<td><a href="mailto:Jenai.Wilmoth@ucsf.edu">Jenai.Wilmoth@ucsf.edu</a></td>
</tr>
<tr>
<td>212522</td>
<td>NCT04904588</td>
<td>Logan, Aaron</td>
<td>ACCESS: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies</td>
<td>Treatment</td>
<td><a href="mailto:Jenai.Wilmoth@ucsf.edu">Jenai.Wilmoth@ucsf.edu</a></td>
</tr>
</tbody>
</table>

last updated 2/1/2024
<table>
<thead>
<tr>
<th>UCSF Protocol No.</th>
<th>ClinicalTrials.gov Protocol</th>
<th>PI Name</th>
<th>Title</th>
<th>Protocol Type</th>
<th>Study Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>212522</td>
<td>NCT04904588</td>
<td>Logan, Aaron</td>
<td>ACCESS: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies</td>
<td>Treatment</td>
<td><a href="mailto:Jenai.Wilmoth@ucsf.edu">Jenai.Wilmoth@ucsf.edu</a></td>
</tr>
<tr>
<td>212518</td>
<td>NCT03870750</td>
<td>Olin, Rebecca</td>
<td>Seamless Phase II-Phase III Randomized Clinical Trial to Identify and Confirm the Most Promising Novel Intervention to Alleviate Morbidity and Mortality after Allogeneic Hematopoietic Cell Transplantation Among Older, Medically Infirm, or Frail Patients with Hematological Diseases</td>
<td>Supportive Care</td>
<td><a href="mailto:Jenai.Wilmoth@ucsf.edu">Jenai.Wilmoth@ucsf.edu</a></td>
</tr>
<tr>
<td>23252</td>
<td>NCT05041309</td>
<td>Logan, Aaron</td>
<td>Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells</td>
<td>Other</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>22702</td>
<td>NCT05577000</td>
<td>Martin, Tom</td>
<td>A Phase 1b Clinical Trial of Anti-BCMA Chimeric Antigen Receptor T cells for Treatment of Relapsed or Refractory Multiple Myeloma</td>
<td>Treatment</td>
<td><a href="mailto:Julie.McCluggage@ucsf.edu">Julie.McCluggage@ucsf.edu</a></td>
</tr>
<tr>
<td>22708</td>
<td>NCT04674813</td>
<td>Martin, Tom</td>
<td>A Phase 1, Multicenter, Open-Label Study of CC-95266 in Subjects with Relapsed and/or Refractory Multiple Myeloma</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>23951</td>
<td>NCT05651932</td>
<td>Chung, Alfred</td>
<td>A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients with Relapsed and Refractory Multiple Myeloma</td>
<td>Treatment</td>
<td><a href="mailto:savannah.berkley@ucsf.edu">savannah.berkley@ucsf.edu</a></td>
</tr>
</tbody>
</table>
### Multiple / Ill-Defined Disease Sites > Solid Tumors

<table>
<thead>
<tr>
<th>UCSF Protocol No.</th>
<th>ClinicalTrials.gov Protocol</th>
<th>PI Name</th>
<th>Title</th>
<th>Protocol Type</th>
<th>Study Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>22954</td>
<td>NCT05032040</td>
<td>Aggarwal, Rahul</td>
<td>A Phase 2 Study of XmAb820717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>23953</td>
<td>NCT05768139</td>
<td>Munster, Pamela</td>
<td>First-in-Human Study of STX-478, a Mutant-Selective PI3Ka Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>22952</td>
<td>NCT04137900</td>
<td>Aggarwal, Rahul</td>
<td>A First-in-Human, Multicenter, Open-label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination With Toripalimab in Subjects With Advanced Solid Malignancies Including Lymphoma</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>22052</td>
<td>NCT05374304</td>
<td>DeBoer, Rebecca</td>
<td>Improving decision making for older adults with cancer: A feasibility pilot study</td>
<td>Health Services Research</td>
<td><a href="mailto:caroline.eskandar@ucsf.edu">caroline.eskandar@ucsf.edu</a></td>
</tr>
<tr>
<td>22801</td>
<td>NCT05297734</td>
<td>Dixit, Niharika</td>
<td>Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults with Cancer</td>
<td>Supportive Care</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>21951</td>
<td>NCT04939610</td>
<td>Koshkin, Vadim</td>
<td>LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients with an Advanced Solid Tumor</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>21708</td>
<td>NCT04626635</td>
<td>Fong, Lawrence</td>
<td>A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>20929</td>
<td>NCT04621435</td>
<td>Hope, Thomas</td>
<td>Imaging of Solid Tumors Using FAP-2286</td>
<td>Diagnostic</td>
<td><a href="mailto:brad.kline@ucsf.edu">brad.kline@ucsf.edu</a>; <a href="mailto:maya.aslam@ucsf.edu">maya.aslam@ucsf.edu</a>; <a href="mailto:nicholas.slater@ucsf.edu">nicholas.slater@ucsf.edu</a></td>
</tr>
<tr>
<td>21705</td>
<td>NCT04799054</td>
<td>Algazi, Alain</td>
<td>Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>22953</td>
<td>NCT05277051</td>
<td>Munster, Pamela</td>
<td>A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants with Selected Advanced Solid Tumors</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>22951</td>
<td>NCT05094336</td>
<td>Munster, Pamela</td>
<td>A phase 1/1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>21702</td>
<td>NCT04250155</td>
<td>Fong, Lawrence</td>
<td>A Phase Ia/Ib, Open-Label, Multicenter, Global, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XmAb24306 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>21953</td>
<td>NCT04449874</td>
<td>Munster, Pamela</td>
<td>A PHASE Ia/Ib DOSE-ESCALATION AND DOSE-EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS G12C MUTATION</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>UCSF Protocol No.</td>
<td>ClinicalTrials.gov Protocol</td>
<td>PI Name</td>
<td>Title</td>
<td>Protocol Type</td>
<td>Study Contact</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------------------</td>
<td>--------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------</td>
<td>-----------------------------------------</td>
</tr>
<tr>
<td>22956</td>
<td>NCT05462717</td>
<td>Munster, Pamela</td>
<td>Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>189510</td>
<td>NCT03682289</td>
<td>Aggarwal, Rahul</td>
<td>Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination with Olaparib or Durvalumab in Patients with Selected Solid Tumor Malignancies</td>
<td>Treatment</td>
<td><a href="mailto:suzannah.henderson@ucsf.edu">suzannah.henderson@ucsf.edu</a></td>
</tr>
<tr>
<td>229510</td>
<td>NCT05694715</td>
<td>Munster, Pamela</td>
<td>Combination Therapy of Niraparib and Irinotecan in Cancers with Mutations in DNA Repair Genes</td>
<td>Treatment</td>
<td><a href="mailto:EarlyPhaseClinicalTrials@ucsf.edu">EarlyPhaseClinicalTrials@ucsf.edu</a></td>
</tr>
<tr>
<td>UCSF Protocol No.</td>
<td>ClinicalTrials.gov Protocol</td>
<td>PI Name</td>
<td>Title</td>
<td>Protocol Type</td>
<td>Study Contact</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------------</td>
<td>---------</td>
<td>-------</td>
<td>---------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Neurologic Oncology &gt; Adult Glioma (Age &gt;= 18)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13106</td>
<td>NCT03739411</td>
<td>Chang, Susan</td>
<td>Pilot Study of Safety and Feasibility of Acquiring Hyperpolarized Imaging in Patients with Gliomas</td>
<td>Diagnostic</td>
<td><a href="mailto:Jane.Rabbitt@ucsf.edu">Jane.Rabbitt@ucsf.edu</a></td>
</tr>
<tr>
<td>Neurologic Oncology &gt; Adult Glioma (Age &gt;= 18) &gt; Grade 2 (Low Grade)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19103</td>
<td>NCT03948490</td>
<td>Taylor, Jennie</td>
<td>Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas</td>
<td>Supportive Care</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>Neurologic Oncology &gt; Adult Brain Tumors, Other (Non-Glioma) &gt; Meningioma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23924</td>
<td>NCT06014905</td>
<td>Villanueva-Meyer, Javier</td>
<td>Pilot/Phase I study of feasibility of acquiring hyperpolarized imaging in patients with meningioma</td>
<td>Diagnostic</td>
<td><a href="mailto:Alya.Briceno@ucsf.edu">Alya.Briceno@ucsf.edu</a>; <a href="mailto:Wendy.Ma@ucsf.edu">Wendy.Ma@ucsf.edu</a></td>
</tr>
<tr>
<td>Neurologic Oncology &gt; Adult Glioma (Age &gt;= 18) &gt; Grade 4 (Glioblastoma or Gliosarcoma) &gt; Recurrent &gt; Surgical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>221022</td>
<td>NCT054842622</td>
<td>Clarke, Jennifer</td>
<td>A Phase 1, Safety Lead-in and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination with Pembrolizumab in Subjects with Recurrent or Progressive Enhancing IDH-1 Mutant Astrocytom</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>Neurologic Oncology &gt; Adult Glioma (Age &gt;= 18) &gt; Grade 4 (Glioblastoma or Gliosarcoma) &gt; Recurrent &gt; Nonsurgical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21105</td>
<td>NCT04478279</td>
<td>Butowski, Nicholas</td>
<td>A Phase 1-2 dose-escalation and expansion study of ST101 in patients with advanced unresectable and metastatic solid tumors</td>
<td>Treatment</td>
<td><a href="mailto:henda.cheikhrouhou@ucsf.edu">henda.cheikhrouhou@ucsf.edu</a></td>
</tr>
<tr>
<td>UCSF Protocol No.</td>
<td>ClinicalTrials.gov Protocol</td>
<td>PI Name</td>
<td>Title</td>
<td>Protocol Type</td>
<td>Study Contact</td>
</tr>
<tr>
<td>-------------------</td>
<td>-----------------------------</td>
<td>---------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------------------------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td>ECOG-ACRIN-EA5163</td>
<td>NCT03793179</td>
<td>Wang, Chia-Ching</td>
<td>EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature driven Analysis</td>
<td>Treatment</td>
<td><a href="mailto:Paul.Couey@ucsf.edu">Paul.Couey@ucsf.edu</a></td>
</tr>
<tr>
<td>22658</td>
<td>NCT05595460</td>
<td>Mulvey, Claire</td>
<td>Phase 1b single arm, open-label trial of RYZ101 in combination with carboplatin + etoposide + atezolizumab in subjects with somatostatin receptor expressing (SSTR+) extensive stage small cell lung cancer (ES-SCLC)</td>
<td>Treatment</td>
<td><a href="mailto:lisa.tan@ucsf.edu">lisa.tan@ucsf.edu</a></td>
</tr>
<tr>
<td>216511</td>
<td>NCT04950075</td>
<td>Wang, Victoria</td>
<td>A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>22871</td>
<td>NCT05208047</td>
<td>Schulte, Brian</td>
<td>(PEAK) A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF CGT9486+SUNITINIB VS SUNITINIB IN SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC GASTROINTESTINAL STROMAL TUMORS</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>216512</td>
<td>NCT03425279</td>
<td>Schulte, Brian</td>
<td>A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF MECBOTAMAB VEDOTIN (BA3011) ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADULT AND ADOLESCENT PATIENTS 12 YEARS AND OLDER WITH ADVANCED SOLID TUMORS</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>23652</td>
<td>NCT05215340</td>
<td>Cheng, Michael</td>
<td>A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS greater than or equal to 50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (Tropion-Lung98)</td>
<td>Treatment</td>
<td><a href="mailto:lisa.tan@ucsf.edu">lisa.tan@ucsf.edu</a></td>
</tr>
<tr>
<td>22659</td>
<td>NCT04302025</td>
<td>Blakely, Collin</td>
<td>NAUTIKA1: A Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer</td>
<td>Treatment</td>
<td><a href="mailto:jameose.johnson@ucsf.edu">jameose.johnson@ucsf.edu</a>; <a href="mailto:lisa.tan@ucsf.edu">lisa.tan@ucsf.edu</a></td>
</tr>
<tr>
<td>21953</td>
<td>NCT04449874</td>
<td>Munster, Pamela</td>
<td>A PHASE Ia/ib DOSE-ESCALATION AND DOSE-EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS G12C MUTATION</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>18653</td>
<td>NCT03375489</td>
<td>Rabow, Michael</td>
<td>Comparative Effectiveness of Early Integrated Telehealth versus In-Person Palliative Care for Patients with Advanced Lung Cancer</td>
<td>Supportive Care</td>
<td><a href="mailto:lisa.tan@ucsf.edu">lisa.tan@ucsf.edu</a></td>
</tr>
<tr>
<td>206510</td>
<td>NCT04077463</td>
<td>Gubens, Matthew</td>
<td>An Open-label Phase 1/ib Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>UCSF Protocol No.</td>
<td>ClinicalTrials.gov Protocol</td>
<td>PI Name</td>
<td>Title</td>
<td>Protocol Type</td>
<td>Study Contact</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------------</td>
<td>-----------</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>23653</td>
<td>NCT05609578</td>
<td>Blakely, Collin</td>
<td>A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation</td>
<td>Treatment</td>
<td><a href="mailto:lisa@ucsf.edu">lisa@ucsf.edu</a></td>
</tr>
<tr>
<td>22657</td>
<td>NCT05375994</td>
<td>Blakely, Collin</td>
<td>A Phase 1/2 Study of Avutometinib in Combination with Adagrasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 204)</td>
<td>Treatment</td>
<td><a href="mailto:lisa@ucsf.edu">lisa@ucsf.edu</a></td>
</tr>
<tr>
<td>22653</td>
<td>NCT05435846</td>
<td>Blakely, Collin</td>
<td>A Multicenter Phase I/ib study of Capmatinib Plus Trametinib in Patients with Metastatic MET exon 14 Skipping Mutation Positive NSCLC</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>22652</td>
<td>NCT05048797</td>
<td>Blakely, Collin</td>
<td>An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>UCSF Protocol No.</td>
<td>ClinicalTrials.gov Protocol</td>
<td>PI Name</td>
<td>Title</td>
<td>Protocol Type</td>
<td>Study Contact</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------------------</td>
<td>---------</td>
<td>-------</td>
<td>---------------</td>
<td>---------------</td>
</tr>
<tr>
<td>19801</td>
<td>NCT05112198</td>
<td>Piawah, Sorbarikor</td>
<td>Digital Symptom Tracking, Patient Engagement and Quality of Life in Advanced Cancer</td>
<td>Health Services Research</td>
<td><a href="mailto:jennifer.luan@ucsf.edu">jennifer.luan@ucsf.edu</a>; <a href="mailto:paige.steiding@ucsf.edu">paige.steiding@ucsf.edu</a></td>
</tr>
<tr>
<td>EA-JCAR017-001-ANDREADIS</td>
<td>NCT04400591</td>
<td>Andreadis, Charalambos</td>
<td>EXPANDED ACCESS PROTOCOL (EAP) FOR PATIENTS RECEIVING LISOCABTAGENE MARALEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE</td>
<td>Other</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>ECOG-ACRIN-EA8184</td>
<td>NCT04597359</td>
<td>Ekstrand, Bradley</td>
<td>A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers</td>
<td>Prevention</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>ALLIANCE-A081801</td>
<td>NCT04267848</td>
<td>Wang, Sunny</td>
<td>ALLIANCE A081801: INTEGRATION OF IMMUNOTHERAPY INTO ADJUVANT THERAPY FOR RESECTED NSCLC: ALCHEMIST CHEMO-IO (ACCIO)</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>23706</td>
<td>NCT04844073</td>
<td>Keenan, Bridget</td>
<td>A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also known as MVC-101), An EGFR x CD3 CONditional Bispecific Redirected Activation (COBRA) Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>160814</td>
<td>NCT02617407</td>
<td>Den Besten, Pamela</td>
<td>Pilot Study: Oral Microbiome and Dental Plaque Control with Livionex Dental Gel in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT)</td>
<td>Prevention</td>
<td><a href="mailto:janelle.urata@ucsf.edu">janelle.urata@ucsf.edu</a></td>
</tr>
<tr>
<td>18863</td>
<td>NCT03767348</td>
<td>Tsai, Katy</td>
<td>An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors</td>
<td>Treatment</td>
<td><a href="mailto:sonia.contrerasmartinez@ucsf.edu">sonia.contrerasmartinez@ucsf.edu</a></td>
</tr>
<tr>
<td>197010</td>
<td>NCT03907852</td>
<td>Oh, David</td>
<td>A PHASE 1/2 SINGLE ARM OPEN-LABEL CLINICAL TRIAL OF GAVOCABTAGENE AUTOLEUCEL (GAVO-CEL) IN PATIENTS WITH ADVANCED MESOTHELIN-EXPRESSING CANCER</td>
<td>Treatment</td>
<td><a href="mailto:julie.McCluggage@ucsf.edu">julie.McCluggage@ucsf.edu</a></td>
</tr>
<tr>
<td>SWOG-LUNGMAP-S1900E</td>
<td>NCT04625647</td>
<td>Wang, Sunny</td>
<td>A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP sub-study)</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>21403</td>
<td>NCT04486352</td>
<td>Alvarez, Edwin</td>
<td>EndoMAP: A Phase I/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer</td>
<td>Treatment</td>
<td><a href="mailto:Chetna.Nangia@ucsf.edu">Chetna.Nangia@ucsf.edu</a>; <a href="mailto:Nathalie.Halley2@ucsf.edu">Nathalie.Halley2@ucsf.edu</a></td>
</tr>
<tr>
<td>21259</td>
<td>NCT04771078</td>
<td>Martin, Tom</td>
<td>Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release</td>
<td>Other</td>
<td><a href="mailto:Jenal.Wilmoth@ucsf.edu">Jenal.Wilmoth@ucsf.edu</a></td>
</tr>
<tr>
<td>230826</td>
<td>NCT04696029</td>
<td>Hastings, Caroline</td>
<td>Phase II Trial of Efomithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma</td>
<td>Treatment</td>
<td><a href="mailto:ailsing.conneally@ucsf.edu">ailsing.conneally@ucsf.edu</a></td>
</tr>
<tr>
<td>221013</td>
<td>NCT05417594</td>
<td>Butowski, Nicholas</td>
<td>A Modular Phase I/II, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Malignancies (CERTIS1)</td>
<td>Treatment</td>
<td><a href="mailto:Rebekah.Garcia2@ucsf.edu">Rebekah.Garcia2@ucsf.edu</a></td>
</tr>
<tr>
<td>228012</td>
<td>NCT05807074</td>
<td>Piper, Merisa</td>
<td>The Impact of Tranexamic Acid in Reducing Hematoma and Seroma Formation in Reconstructive Post-Oncologic Breast Surgery</td>
<td>Supportive Care</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>UCSF Protocol No.</td>
<td>ClinicalTrials.gov Protocol</td>
<td>PI Name</td>
<td>Title</td>
<td>Protocol Type</td>
<td>Study Contact</td>
</tr>
<tr>
<td>-------------------</td>
<td>-----------------------------</td>
<td>--------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td>230827</td>
<td>NCT05533775</td>
<td>Michlitsch, Jennifer</td>
<td>A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoinmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma</td>
<td>Treatment</td>
<td><a href="mailto:teran.nieman@ucsf.edu">teran.nieman@ucsf.edu</a></td>
</tr>
<tr>
<td>227011</td>
<td>NCT04986865</td>
<td>Keenan, Bridget</td>
<td>A First-in-Human Phase I Trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas</td>
<td>Treatment</td>
<td><a href="mailto:Elaine.Esler@ucsf.edu">Elaine.Esler@ucsf.edu</a></td>
</tr>
<tr>
<td>23552</td>
<td>NCT05946603</td>
<td>Nguyen, Hao</td>
<td>Phase 2 Multi-Center Randomized Controlled Feasibility Study of IS-002 in Subjects Undergoing Robotic-Assisted Radical Prostatectomy Using the da Vinci® Surgical System With Firefly® Fluorescence Imaging</td>
<td>Other</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>RTOG-1216</td>
<td>NCT01810913</td>
<td>Chan, Jason</td>
<td>Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck</td>
<td>Treatment</td>
<td><a href="mailto:jamese.johnson@ucsf.edu">jamese.johnson@ucsf.edu</a></td>
</tr>
<tr>
<td>19521</td>
<td>NCT03869190</td>
<td>Friedlander, Terence</td>
<td>A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>ECOG-ACRIN--E4512</td>
<td>NCT02201992</td>
<td>Wang, Sunny</td>
<td>A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>ECOG-ACRIN-EA2185</td>
<td>NCT04239573</td>
<td>Kirkwood, Kimberly</td>
<td>Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs</td>
<td>Screening</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>202014</td>
<td>NCT04588038</td>
<td>Kang, Hyunseok</td>
<td>A Window of Opportunity Trial of NT-17 in Patients with Locally Recurrent Squamous Cell Carcinoma of Head and Neck (SCCHN) Undergoing Salvage Surgery</td>
<td>Treatment</td>
<td><a href="mailto:angelica.valadez@ucsf.edu">angelica.valadez@ucsf.edu</a></td>
</tr>
<tr>
<td>21955</td>
<td>NCT04143711</td>
<td>Munster, Pamela</td>
<td>A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>21631</td>
<td>NCT04855357</td>
<td>Vijayaraghavan, Maya</td>
<td>A community-based trial of a voluntary smoke-free home intervention in permanent supportive housing for formerly homeless adults</td>
<td>Prevention</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>NRG-GI005</td>
<td>NCT04068103</td>
<td>Malhotra, Akshiv</td>
<td>Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>SWOG-S1827</td>
<td>NCT04155034</td>
<td>Wang, Sunny</td>
<td>MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>22703</td>
<td>NCT05239143</td>
<td>Oh, David</td>
<td>A PHASE 1 DOSE ESCALATION AND EXPANDED COHORT STUDY OF P-MUC1C-ALLO1 IN ADULT SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>21636</td>
<td>NCT04627922</td>
<td>Herbst, Ellen</td>
<td>N-Acetylcysteine for Smoking Cessation in Cigarette-Cannabis Co-Users: A Randomized Controlled Trial</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>ALLIANCE-A211801</td>
<td>NCT04711109</td>
<td>Munster, Pamela</td>
<td>BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mutation</td>
<td>Prevention</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>UCSF Protocol No.</td>
<td>ClinicalTrials.gov Protocol</td>
<td>PI Name</td>
<td>Title</td>
<td>Protocol Type</td>
<td>Study Contact</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------------</td>
<td>------------------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>22958</td>
<td>NCT05746208</td>
<td>Bergsland, Emily</td>
<td>A Phase II study of lenvatinib plus pembrolizumab in well differentiated G3 neuroendocrine tumors</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>221018</td>
<td>NCT05383872</td>
<td>de Groot, John</td>
<td>A Pivotal Study to Evaluate the Safety and Effectiveness of Exablate Model 4000 using Microbubble Resonators to Temporarily Mediate Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with Glioblastoma Brain Tumors</td>
<td>Diagnostic</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>23703</td>
<td>NCT04969315</td>
<td>Fong, Lawrence</td>
<td>Phase I/II First-in-Human Study of TT-10 as a Single Agent in Participants with Advanced Selected Solid Tumors</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>16751</td>
<td>NCT03011684</td>
<td>Rosen, Mitchell</td>
<td>Fertility Preservation Using Tamoxifen or Letrozole in Estrogen Sensitive Tumors Trial (TALES Trial)</td>
<td>Supportive Care</td>
<td><a href="mailto:Flor.Juarez-Hernandez@ucsf.edu">Flor.Juarez-Hernandez@ucsf.edu</a></td>
</tr>
<tr>
<td>19653</td>
<td>NCT04123535</td>
<td>Bucknor, Matthew</td>
<td>Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma</td>
<td>Treatment</td>
<td><a href="mailto:louise.magat@ucsf.edu">louise.magat@ucsf.edu</a></td>
</tr>
<tr>
<td>19089</td>
<td>NCT03509961</td>
<td>Higham, Christine</td>
<td>A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allergenic hematopoietic cell transplanation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative</td>
<td>Treatment</td>
<td><a href="mailto:magruderk@radonc.ucsf.edu">magruderk@radonc.ucsf.edu</a></td>
</tr>
<tr>
<td>197021</td>
<td>NCT04221542</td>
<td>Aggarwal, Rahul</td>
<td>A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-resistant Prostate Cancer</td>
<td>Treatment</td>
<td><a href="mailto:Julie.McCluggage@ucsf.edu">Julie.McCluggage@ucsf.edu</a></td>
</tr>
<tr>
<td>2016-100</td>
<td>NCT02679144</td>
<td>Agrawal, Anurag</td>
<td>Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)</td>
<td>Prevention</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>20527</td>
<td>NCT04626479</td>
<td>Desai, Arpita</td>
<td>A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (KEYMAKER-U03): Substudy 03A</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>219516</td>
<td>NCT04662580</td>
<td>Aggarwal, Rahul</td>
<td>A Phase 1/2, Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of ARX517 as Monotherapy and in Combination Regimens, with Randomized Comparison to Investigator's Choice of Treatment, in Subjects with Metastatic Castration-resistant Prostate Cancer who are Resistant or Refractory to Prior Standard Therapies</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>21106</td>
<td>NCT05163080</td>
<td>Butowski, Nicholas</td>
<td>Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)</td>
<td>Treatment</td>
<td><a href="mailto:Meghan.Tedesco@ucsf.edu">Meghan.Tedesco@ucsf.edu</a></td>
</tr>
<tr>
<td>228013</td>
<td>NCT05520866</td>
<td>Finlayson, Emily</td>
<td>PREHABPAL: A DIGITAL TOOL TO HELP FRAIL ELDERS PREPARE FOR SURGERY</td>
<td>Supportive Care</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>23952</td>
<td>NCT05107674</td>
<td>Munster, Pamela</td>
<td>A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>23702</td>
<td>NCT04471727</td>
<td>Aggarwal, Rahul</td>
<td>A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 with Alezolizumab in Patients with Advanced Cancers Associated with Expression of Delta-like Canonical Notch Ligand 3 (DLL3)</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>UCSF Protocol No.</td>
<td>ClinicalTrials.gov Protocol</td>
<td>PI Name</td>
<td>Title</td>
<td>Protocol Type</td>
<td>Study Contact</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------------</td>
<td>-----------------------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------</td>
<td>---------------------------------------------------</td>
</tr>
<tr>
<td>161016</td>
<td>NCT04540107</td>
<td>Chang, Susan</td>
<td>Metabolic Imaging of Patients with Lower Grade Glioma using Hyperpolarized 13C Pyruvate</td>
<td>Diagnostic</td>
<td><a href="mailto:Wendy.Ma@ucsf.edu">Wendy.Ma@ucsf.edu</a></td>
</tr>
<tr>
<td>177017</td>
<td>NCT03435796</td>
<td>Andreadis, Charalambos</td>
<td>LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH CAR T CELLS</td>
<td>Other</td>
<td><a href="mailto:Julie.McCluggage@ucsf.edu">Julie.McCluggage@ucsf.edu</a></td>
</tr>
<tr>
<td>ALLIANCE-A151216</td>
<td>NCT02194738</td>
<td>Wang, Sunny</td>
<td>Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)</td>
<td>Screening</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>197017</td>
<td>NCT04370509</td>
<td>Oh, David</td>
<td>A Phase II Study of Perioperative Pembrolizumab-Based Therapy in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma Prior to Cytoreductive Nephrectomy or Metastasectomy</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>24083</td>
<td>NCT02559778</td>
<td>Agrawal, Anurag</td>
<td>Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDS-PLAN): A Study Using Molecular Guided Therapy with Induction Chemotherapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma</td>
<td>Treatment</td>
<td><a href="mailto:nicole.elzie-tuttle@ucsf.edu">nicole.elzie-tuttle@ucsf.edu</a>; <a href="mailto:teran.nieman@ucsf.edu">teran.nieman@ucsf.edu</a></td>
</tr>
<tr>
<td>20708</td>
<td>NCT03625037</td>
<td>Andreadis, Charalambos</td>
<td>A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>21751</td>
<td>NCT05456373</td>
<td>Wong, Jasmine</td>
<td>Intraoperative Use of ClearEdge Device in Breast Conserving Surgery</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>ALLIANCE-A021901</td>
<td>NCT04665739</td>
<td>Bergsland, Emily</td>
<td>Randomized Phase II Trial of Lutetium Lu177 DOTATATE Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>215514</td>
<td>NCT05324098</td>
<td>Bomo, Hala</td>
<td>Leveraging technology (STAND-T) to achieve equity for men with prostate cancer on androgen deprivation therapy</td>
<td>Health Services Research</td>
<td><a href="mailto:christine.wang@ucsf.edu">christine.wang@ucsf.edu</a></td>
</tr>
<tr>
<td>21208</td>
<td>NCT05152927</td>
<td>Duh, Quan-Yang</td>
<td>Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands during Parathyroidectomy</td>
<td>Prevention</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>21633</td>
<td>NCT04707911</td>
<td>Ling, Pamela</td>
<td>Social Media Intervention to Stop Nicotine and Cannabis Vaping Among Adolescents</td>
<td>Prevention</td>
<td><a href="mailto:colin.jones@ucsf.edu">colin.jones@ucsf.edu</a>; <a href="mailto:sarah.rosen@ucsf.edu">sarah.rosen@ucsf.edu</a></td>
</tr>
<tr>
<td>215510</td>
<td>NCT05113537</td>
<td>Koshkin, Vadim</td>
<td>Phase I/II Study of CDK4/6 Inhibition with Abemaciclib to Upregulate PSMA Expression Prior to 177Lu-PSMA-617 Treatment in Patients with Metastatic Castrate Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Chemotherapy</td>
<td>Treatment</td>
<td><a href="mailto:GUtrials@ucsf.edu">GUtrials@ucsf.edu</a></td>
</tr>
<tr>
<td>22925</td>
<td>NCT05851378</td>
<td>Chang, Susan</td>
<td>Hyperpolarized carbon-13 alpha-ketoglutarate metabolic imaging in IDH mutant glioma</td>
<td>Diagnostic</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>22709</td>
<td>NCT05519449</td>
<td>Fong, Lawrence</td>
<td>A PHASE 1, OPEN-LABEL, MULTICENTER STUDY OF JANX007 IN SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER</td>
<td>Treatment</td>
<td><a href="mailto:Kiev.Gimpel-tetra@ucsf.edu">Kiev.Gimpel-tetra@ucsf.edu</a>; <a href="mailto:andrea.skafe@ucsf.edu">andrea.skafe@ucsf.edu</a></td>
</tr>
<tr>
<td>23104</td>
<td>NCT04528680</td>
<td>Butowski, Nicholas</td>
<td>Phase I/II trial of blood-brain barrier opening with the SonoCloud-9 implantable ultrasound device and treatment with albumin-bound pacitaxel and carboplatin in patients with recurrent glioblastoma</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>UCSF Protocol No.</td>
<td>ClinicalTrials.gov Protocol</td>
<td>PI Name</td>
<td>Title</td>
<td>Protocol Type</td>
<td>Study Contact</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------------</td>
<td>---------</td>
<td>-------</td>
<td>---------------</td>
<td>---------------</td>
</tr>
<tr>
<td>CTSU-EA1151</td>
<td>NCT03233191</td>
<td>Freimanis, Rita</td>
<td>Tomosynthesis Mammographic Imaging Screening Trial (TMIST)</td>
<td>Screening</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>SWOG-LUNGMAP</td>
<td>NCT03851445</td>
<td>Eftimie, Bogdan</td>
<td>A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)</td>
<td>Screening</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>194522</td>
<td>NCT04430452</td>
<td>Feng, Mary</td>
<td>Phase II Trial of Durvalumab (MED14736) with/without Tremelimumab for Advanced Hepatocellular Carcinoma after Palliative Hypofractionated Radiotherapy</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>19703</td>
<td>NCT04545762</td>
<td>Andreadis, Charalambos</td>
<td>A Phase 1 Clinical Trial of Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma</td>
<td>Treatment</td>
<td><a href="mailto:Julie.McCluggage@ucsf.edu">Julie.McCluggage@ucsf.edu</a></td>
</tr>
<tr>
<td>195511</td>
<td>NCT04335682</td>
<td>Kwon, Daniel</td>
<td>ARACOG: A Randomized Phase II Study of Androgen Receptor Directed Therapy on COGnitive Function in Patients Treated with Darolutamide or Enzalutamide</td>
<td>Other</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>19109</td>
<td>NCT04659811</td>
<td>Oberheim Bush, Nancy Ann</td>
<td>A Phase II Study of Stereotactic Radiosurgery in Conjunction with the PD-1 Inhibitor, Pembrolibumab for the Treatment of Recurrent Meningioma</td>
<td>Treatment</td>
<td><a href="mailto:karishma.kumar@ucsf.edu">karishma.kumar@ucsf.edu</a></td>
</tr>
<tr>
<td>219511</td>
<td>NCT04553692</td>
<td>Munster, Pamela</td>
<td>An Open-Label, Multicenter, Phase 1a/1b Study of Apitabart (IGM-8444) as a Single Agent and in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>226310</td>
<td>NCT05829824</td>
<td>Tsoh, Janice</td>
<td>Connect Cancer Patients to Tobacco Cessation Care by Automated Interactive Outreach</td>
<td>Health Services Research</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>23052</td>
<td>NCT05753007</td>
<td>Yu, Diana</td>
<td>Clinical Utility of Management of Patients with CT and LDCT Identified Pulmonary Nodules Using the Percepta Nasal Swab Classifier - with Familiarization</td>
<td>Diagnostic</td>
<td><a href="mailto:Alma.Andrade@ucsf.edu">Alma.Andrade@ucsf.edu</a></td>
</tr>
<tr>
<td>23101</td>
<td>NCT05753007</td>
<td>Butowski, Nicholas</td>
<td>A Randomized, Double-blind, Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients</td>
<td>Supportive Care</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>23954</td>
<td>NCT04972110</td>
<td>Aggarwal, Rahul</td>
<td>Phase 1b/2 Study of ATR Inhibitor RP-3500 and PARP Inhibitor Combinations in Patients with Molecularly Selected Cancers (ATTACC)</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>20-30544</td>
<td>NCT04301843</td>
<td>Michlitsch, Jennifer</td>
<td>Phase II Trial of Efllornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma</td>
<td>Treatment</td>
<td><a href="mailto:nicole.elzie-tuttle@ucsf.edu">nicole.elzie-tuttle@ucsf.edu</a></td>
</tr>
<tr>
<td>20926</td>
<td>NCT04927663</td>
<td>Aggarwal, Rahul</td>
<td>A First-in-Human, Phase I PET imaging study of 11C-YJH08, a Selective Glucocorticoid Receptor-Targeting Agent, in Patients with Advanced Solid Tumor Malignancies</td>
<td>Diagnostic</td>
<td><a href="mailto:khadija.siddiqua@ucsf.edu">khadija.siddiqua@ucsf.edu</a></td>
</tr>
<tr>
<td>21457</td>
<td>NCT05028725</td>
<td>Van Loon, Katherine</td>
<td>Investigation of a Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma</td>
<td>Diagnostic</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>21727</td>
<td>NCT05021185</td>
<td>Tsoh, Janice</td>
<td>Interactive Mobile Doctor (iMD) to Promote Tobacco Cessation among Cancer Patients</td>
<td>Health Services Research</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>210813</td>
<td>NCT05478837</td>
<td>Mueller, Sabine</td>
<td>PNOC018 A Phase 1 Clinical Trial of Autologous T Cells Expressing a TCR Specific for H3.3K27M with Inhibition of Endogenous TCR (KIND T Cells) in HLA-A*0201-positive Participants with Newly Diagnosed H3.3K27M-positive Diffuse Midline Gliomas</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>22637</td>
<td>NCT03950427</td>
<td>Leutwyler, Heather</td>
<td>VIP Smoking Cessation Intervention for Adults with Serious Mental Illness</td>
<td>Prevention</td>
<td><a href="mailto:Erin.Hubbard@ucsf.edu">Erin.Hubbard@ucsf.edu</a></td>
</tr>
<tr>
<td>UCSF Protocol No.</td>
<td>ClinicalTrials.gov Protocol</td>
<td>PI Name</td>
<td>Title</td>
<td>Protocol Type</td>
<td>Study Contact</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------------------</td>
<td>---------</td>
<td>-------</td>
<td>---------------</td>
<td>---------------</td>
</tr>
<tr>
<td>NRG-GU009</td>
<td>NCT04513717</td>
<td>Ekstrand, Bradley</td>
<td>PARALLEL PHASE III RANDOMIZED TRIALS FOR HIGH RISK PROSTATE CANCER EVALUATING DE-INTENSIFICATION FOR LOWER GENOMIC RISK AND INTENSIFICATION OF CONCURRENT THERAPY FOR HIGHER GENOMIC RISK WITH RADIATION (PREDICT-RT) *Prostate RNA Expression/Decipher To Individualize Concurrent Therapy with Radiation</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>224523</td>
<td>NCT05746195</td>
<td>Van Blarigan, Erin</td>
<td>Optimization of Adaptive Text Messages for Cancer Survivors II (OATS II)</td>
<td>Supportive Care</td>
<td><a href="mailto:paige.steiding@ucsf.edu">paige.steiding@ucsf.edu</a></td>
</tr>
<tr>
<td>229511</td>
<td>NCT05315700</td>
<td>Cheng, Michael</td>
<td>An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination with Chemotherapy, in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>20551</td>
<td>NCT04471974</td>
<td>Aggarwal, Rahul</td>
<td>A Phase 2 Study of BET Bromodomain Inhibitor ZEN-3694 in Combination with Enzalutamide Plus Pembrolizumab in Metastatic Castration Resistant Prostate Cancer</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>EA-MAP-12519-ANDREADIS</td>
<td>NCT03601442</td>
<td>Andreadis, Charalampos</td>
<td>Managed Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release (expanded access)</td>
<td>Other</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>ALLIANCE-A221805</td>
<td>NCT04137107</td>
<td>Eftimie, Bogdan</td>
<td>Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study</td>
<td>Supportive Care</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>ECOG-ACRIN-EA5182</td>
<td>NCT04181060</td>
<td>Eftimie, Bogdan</td>
<td>Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>230825</td>
<td>NCT02303821</td>
<td>Agrawal, Anurag</td>
<td>Phase 1b/2 Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>NRG-CC008</td>
<td>NCT04251052</td>
<td>Chen, Lee-may</td>
<td>A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCK]</td>
<td>Prevention</td>
<td><a href="mailto:Chetna.Nangia@ucsf.edu">Chetna.Nangia@ucsf.edu</a>; <a href="mailto:Nathalie.Halley2@ucsf.edu">Nathalie.Halley2@ucsf.edu</a></td>
</tr>
<tr>
<td>21622</td>
<td>NCT05074264</td>
<td>Palefsky, Joel</td>
<td>Optimization of screening algorithms for cervical and anal high-grade squamous intraepithelial lesions in people living with HIV in Mexico and Puerto Rico</td>
<td>Screening</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>22401</td>
<td>NCT04931342</td>
<td>Alvarez, Edwin</td>
<td>GOG-3051: A PHASE II, OPEN-LABEL, MULTICENTER, PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF BIOMARKER-DRIVEN THERAPIES IN PATIENTS WITH PERSISTENT OR RECURRENT RARE EPITHELIAL OVARIAN TUMORS</td>
<td>Treatment</td>
<td><a href="mailto:Chetna.Nangia@ucsf.edu">Chetna.Nangia@ucsf.edu</a></td>
</tr>
<tr>
<td>221017</td>
<td>NCT05303467</td>
<td>Butowski, Nicholas</td>
<td>A Feasibility Study to Evaluate the Safety of the TheraSphereTM Glioblastoma (GBM) Device in Patients with Recurrent GBM</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>22103</td>
<td>NCT05023551</td>
<td>Butowski, Nicholas</td>
<td>A Phase 1 Study of DSP-0390 in Patients with Recurrent High-Grade Glioma</td>
<td>Treatment</td>
<td><a href="mailto:MariaLoudette.Bautista@ucsf.edu">MariaLoudette.Bautista@ucsf.edu</a></td>
</tr>
<tr>
<td>SWOG-S1918</td>
<td>NCT04799275</td>
<td>Ekstrand, Bradley</td>
<td>A PHASE II/III RANDOMIZED STUDY OF R-MINICHOP WITH OR WITHOUT CC-486 (ORAL AZACITIDINE) IN PARTICIPANTS AGE 75 YEARS OR OLDER WITH NEWLY DIAGNOSED DIFFUSE LARGE B CELL LYMPHOMA, GRADE IIIIB FOLLICULAR LYMPHOMA, TRANSFORMED LYMPHOMA, AND HIGH-GRADE B-CELL LYMPHOMAS WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>UCSF Protocol No.</td>
<td>ClinicalTrials.gov Protocol</td>
<td>PI Name</td>
<td>Title</td>
<td>Protocol Type</td>
<td>Study Contact</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------------</td>
<td>------------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>22639</td>
<td>NCT05351606</td>
<td>Bialous, Stella</td>
<td>Integrating tobacco use cessation into HIV Care and Treatment in Ministry of Health Facilities in Kisumu County, Kenya</td>
<td>Prevention</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>22957</td>
<td>NCT05252416</td>
<td>Munster, Pamela</td>
<td>A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
<tr>
<td>227520</td>
<td>NCT05563220</td>
<td>Rugo, Hope</td>
<td>A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE)</td>
<td>Treatment</td>
<td><a href="mailto:Amy.Deluca@ucsf.edu">Amy.Deluca@ucsf.edu</a></td>
</tr>
<tr>
<td>SWOG-S1914</td>
<td>NCT04214262</td>
<td>Wang, Sunny</td>
<td>A RANDOMIZED PHASE III TRIAL OF INDUCTION/CONSOLIDATION ATEZOLIZUMAB (NSC #783608) + SBRT VERSUS SBRT ALONE IN HIGH RISK, EARLY STAGE NSCLC</td>
<td>Treatment</td>
<td>1-877-827-3222</td>
</tr>
</tbody>
</table>